en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
3/2024
vol. 99
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Artykuł przeglądowy

Immune thrombocytopaenia in children and adolescents – current management and Polish perspective

Marta Andrzejewska
1
,
Ewelina Truszkowska
1
,
Katarzyna Derwich
1

  1. Department of Paediatric Oncology, Haematology, and Transplantology, Poznań University of Medical Sciences, Poznań, Poland
Pediatr Pol 2024; 99 (3): 225-232
Data publikacji online: 2024/09/20
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Immune thrombocytopaenia (ITP) is the most common cause of acquired thrombocytopaenia diagnosed in paediatric patients. It is described as an isolated thrombocytopaenia without other factors, which may cause a decrease in platelets. Therefore, the diagnosis is of exclusion. Over the last few years, its management has significantly developed, and a paradigm switch in second-line treatment is being observed. Currently, thrombopoietin receptor agonists (TPO-RA) are available in Poland, which reduce the need for splenectomy in affected patients. The use of thrombopoietin receptor agonists has also provoked a change in definitions, especially concerning refractory ITP. This review focuses on an overview of currently recommended diagnostics and treatment of ITP, ongoing research concerning genetic predisposition, the use of TPO-RA, other immunosuppressive agents, and the role of splenectomy. We summarise congenital thrombocytopaenic disorders, which are the most often mistaken as ITP and need to be considered in the differential diagnosis.